Abstract:Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.

Nuclear Receptor ROR/: Exciting Modulators in Metabolic Syndrome and Related Disorders

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

ROR Nuclear Receptors: Structures, Related Diseases, and Drug Discovery

Metabolic Nuclear Receptors and Metabolic Syndrome

Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders

Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases

Nuclear Hormone Receptors PXR and CAR and Metabolic Diseases

Roles of distinct nuclear receptors in diabetic cardiomyopathy

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Nuclear Receptors and Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature

A review of the molecular design and biological activities of RXR agonists

Targeting Nuclear Receptors with Marine Natural Products

Research status of microRNA-dependent control of drug metabolic enzymes and transporters mediated by nuclear receptors

Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome

PPARδ and Its Role in the Metabolic Syndrome

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease

A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis-associated molecular pattern receptors

The Role of the Nrf2/Keap1 Pathway in Obesity and Metabolic Syndrome

Dietary regulation of peroxisome proliferator-activated receptors in metabolic syndrome